4D Molecular Therapeutics Shares Surge 50.89% on Positive Clinical Trial Results

4D Molecular Therapeutics (FDMT) shares surged 50.89% in pre-market trading on August 1, 2025, driven by positive clinical trial results and regulatory updates.

The company's 4D-150 treatment for diabetic macular edema (DME) showed promising results in the SPECTRA clinical trial, demonstrating tolerability and consistent, durable clinical activity over a 60-week period. This news has significantly boosted investor confidence in the company's therapeutic potential.

4D Molecular Therapeutics has been actively updating the market on the progress of its clinical trials, with recent announcements highlighting the positive outcomes of the SPECTRA trial. These updates have been well-received by investors, contributing to the stock's recent gains.

The positive clinical trial results and regulatory updates have positioned 4D Molecular Therapeutics as a key player in the biotechnology sector, with investors eagerly awaiting further developments in the company's pipeline.